GXO Logistics, Inc.

**Signal Note: Driehaus Capital Initiates GXO Logistics Position** This move is notable primarily as a portfolio diversification signal rather than a biotech-specific catalyst—GXO is a contract logistics provider, not a drug developer, suggesting Driehaus may be rotating capital away from pure biotech into adjacent healthcare infrastructure plays. The $5.2M position size is modest relative to typical Driehaus biotech bets, indicating this is likely a tactical healthcare supply-chain hedge rather than a conviction biotech thesis.